AVROBIO Inc. (AVRO) – Business Wire
-
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure
-
Tectonic Therapeutic Announces Participation at Investor Conferences in March
-
AVROBIO and Tectonic Therapeutic Announce Merger
-
AVROBIO to Explore Strategic Alternatives
-
AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million
-
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
-
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting
-
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
-
AVROBIO Announces Leadership Transition
-
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
-
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference
-
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
-
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
-
AVROBIO to Share Comprehensive Gaucher Disease Program Update
-
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
-
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
-
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
-
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
-
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
-
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
-
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Ther
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO to Participate in Four Upcoming Investor Conferences in September
-
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO to Participate in Two Upcoming Investor Conferences in August
-
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
-
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
-
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
-
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
-
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
-
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
-
AVROBIO to Present at Two Upcoming Investor Conferences in March
-
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
-
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
-
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
AVROBIO Reprioritizes Pipeline Programs
Back to AVRO Stock Lookup
